Pravastatin vs rosuvastatin
Pro Research Analysisby 
Searched over 200M research papers
LDL Cholesterol Lowering Efficacy: Rosuvastatin vs Pravastatin
Multiple studies consistently show that rosuvastatin is more effective than pravastatin at lowering low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. In head-to-head trials, even low doses of rosuvastatin (5–10 mg) produced greater reductions in LDL-C than higher doses of pravastatin (20–40 mg) 15610. For example, one study found that after 12 weeks, rosuvastatin 5 mg and 10 mg reduced LDL-C by 39–47%, compared to 26.5% for pravastatin 20 mg . Another trial showed that 87–89% of patients on rosuvastatin achieved LDL-C goals, compared to 53–60% on pravastatin 15610. This superior efficacy was also observed in special populations, such as HIV-infected patients on protease inhibitors .
Effects on Other Lipid Parameters
Rosuvastatin not only lowers LDL-C more effectively, but also tends to improve other lipid parameters, such as total cholesterol and triglycerides, more than pravastatin 58. In comparative studies, rosuvastatin led to greater reductions in total cholesterol and triglycerides, and a higher percentage of patients reached recommended cholesterol targets 5810.
Metabolic and Glucose Homeostasis Effects
While both statins improve cholesterol profiles, their effects on glucose metabolism differ. Rosuvastatin has been associated with increased insulin resistance and decreased insulin sensitivity, as shown by higher insulin levels and lower adiponectin in both human and animal studies 237. In contrast, pravastatin appears to improve insulin sensitivity, lower insulin levels, and increase adiponectin 237. These differences may be clinically relevant, especially for patients at risk of diabetes or with impaired glucose tolerance.
Liver Uptake and Tissue Distribution
Both rosuvastatin and pravastatin are taken up by the liver through active transport, but rosuvastatin is absorbed more efficiently and selectively by liver cells 49. This liver-specific uptake is considered beneficial for targeting cholesterol synthesis while minimizing exposure to other tissues 49.
Safety and Tolerability
Both rosuvastatin and pravastatin are generally well tolerated, with similar safety profiles in clinical trials 1568. Severe adverse events are rare, and no significant differences in liver, kidney, or muscle toxicity have been reported between the two drugs 1568.
Conclusion
Rosuvastatin is more potent than pravastatin in lowering LDL cholesterol and helping patients achieve cholesterol targets. However, rosuvastatin may have less favorable effects on insulin sensitivity and glucose metabolism compared to pravastatin. Both drugs are well tolerated and have a good safety profile, but the choice between them may depend on individual patient risk factors, especially regarding diabetes and metabolic health.
Sources and full results
Most relevant research papers on this topic